ELIZA KIT BUSINESS

Biomarker Measurement Platform Business

Strategic Development Based on the ATN Framework

Business Strategy Aligned with Market Transformation

In the research and diagnostic fields of Alzheimer’s disease, evaluations based on the ATN framework (Amyloid, Tau, Neurodegeneration) are becoming internationally standardized.
As this shift progresses, the need for multi-marker assessment—rather than reliance on a single biomarker—is rapidly increasing.

ATN-Centered Business Development

In response to this evolving market structure, we are advancing the development and commercialization of ELISA kits that cover all ATN domains (A, T, and N).

This approach enables:

Moving beyond single-marker products
Addressing the growing demand for integrated, multi-dimensional evaluation
Supporting applications across research, drug discovery, and diagnostic field

Positioning as a Measurement Platform

Our ELISA kits are designed not as standalone products, but as components of a broader measurement platform aligned with the ATN framework.

For customers, this provides:

A unified measurement environment that supports continuous use
Expandability through the addition of new biomarkers
Seamless transition from research to applied and clinical settings

Alignment with a Recurring-Revenue Model

Because the ATN framework inherently requires combinations of multiple biomarkers, it naturally supports a structure with strong continuity and expandability in reagent demand.

Leveraging this characteristic, we have built a recurring-revenue business model that enables:

Continuous revenue through kit sales
Revenue expansion through the addition of new biomarkers
Long-term retention of the customer base

Scalability Through Integration with KI-ZA-SHI

This business further evolves toward automation and standardization of measurement through integration with our fully automated ELISA system, KI-ZA-SHI.